These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37026168)

  • 21. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
    Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
    Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacituzumab Govitecan-hziy in Breast Cancer.
    Kwapisz D
    Am J Clin Oncol; 2022 Jul; 45(7):279-285. PubMed ID: 35728046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    Bardia A; Rugo HS; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Kalinsky K; Cortés J; Shaughnessy JO; Diéras V; Carey LA; Gianni L; Piccart-Gebhart M; Loibl S; Yoon OK; Pan Y; Hofsess S; Phan SC; Hurvitz SA
    J Clin Oncol; 2024 May; 42(15):1738-1744. PubMed ID: 38422473
    [No Abstract]   [Full Text] [Related]  

  • 24. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
    Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
    Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
    Loibl S; Loirat D; Tolaney SM; Punie K; Oliveira M; Rugo HS; Bardia A; Hurvitz SA; Brufsky AM; Kalinsky K; Cortés J; O'Shaughnessy JA; Dieras V; Carey LA; Gianni L; Gharaibeh M; Preger L; Phan S; Chang L; Shi L; Piccart MJ
    Eur J Cancer; 2023 Jan; 178():23-33. PubMed ID: 36379186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
    Kang C
    Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    De Moura A; Loirat D; Vaillant S; Korbi S; Kiavue N; Bello Roufai D; Escalup L; Desmaris R; Vaflard P; Cottu P; Pierga JY; Bidard FC; Cabel L; Acramel A
    Breast Cancer; 2024 Jul; 31(4):572-580. PubMed ID: 38600429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.
    Reinisch M; Bruzas S; Spoenlein J; Shenoy S; Traut A; Harrach H; Chiari O; Cremer E; Ataseven B; Gubelt L; Kuemmel S
    Ther Adv Med Oncol; 2023; 15():17588359231200454. PubMed ID: 37789989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
    Kalinsky K; Diamond JR; Vahdat LT; Tolaney SM; Juric D; O'Shaughnessy J; Moroose RL; Mayer IA; Abramson VG; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Goswami T; Wegener WA; Bardia A
    Ann Oncol; 2020 Dec; 31(12):1709-1718. PubMed ID: 32946924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back.
    Rossi V; Turati A; Rosato A; Carpanese D
    Front Immunol; 2024; 15():1447280. PubMed ID: 39211043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
    Rugo HS; Tolaney SM; Loirat D; Punie K; Bardia A; Hurvitz SA; O'Shaughnessy J; Cortés J; Diéras V; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo M; Itri LM; Kalinsky K
    NPJ Breast Cancer; 2022 Aug; 8(1):98. PubMed ID: 36038616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
    Xie J; Li S; Li Y; Li J
    BMC Health Serv Res; 2023 Jun; 23(1):706. PubMed ID: 37386633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
    Cher BP; Goh S; Aziz MIA; Wong G; Ng Chee Hui R; Ong BS; Ng KH
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):217-225. PubMed ID: 38149409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.
    Rizzo A; Rinaldi L; Massafra R; Cusmai A; Guven DC; Forgia D; Latorre A; Giotta F
    Future Oncol; 2024; 20(20):1427-1434. PubMed ID: 38864297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
    Hanna D; Merrick S; Ghose A; Devlin MJ; Yang DD; Phillips E; Okines A; Chopra N; Papadimatraki E; Ross K; Macpherson I; Boh ZY; Michie CO; Swampillai A; Gupta S; Robinson T; Germain L; Twelves C; Atkinson C; Konstantis A; Riddle P; Cresti N; Naik JD; Borley A; Guppy A; Schmid P; Phillips M
    Br J Cancer; 2024 Jun; 130(12):1916-1920. PubMed ID: 38658782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
    Baek G; Jung L; Duong A; Gralow J
    J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    Nagayama A; Vidula N; Bardia A
    Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.